| Předmět: |
|
| Zdroj: |
Drug Week; 10/8/2024, p1476-1476, 1p |
| Abstrakt: |
A recent study conducted at Ohio State University examined the safety and efficacy of the drug felzartamab in treating primary membranous nephropathy (PMN), a kidney disease caused by autoantibodies. The study involved two cohorts of patients with PMN, one with newly diagnosed or relapsed PMN and the other with PMN refractory to immunosuppressive therapy. The results showed that felzartamab was well-tolerated and led to immunologic responses and improvements in proteinuria and serum albumin in some patients. This research provides valuable insights into potential treatment options for PMN. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
